Definitive Healthcare signs confidentiality agreement

The agreement sets 12-month non-solicitation and standstill provisions, with certain restrictions subject to prior written consent and exceptions.

Rhea-AI Filing Summary

Definitive Healthcare Corp. (DH) reports that Advent International, L.P. entered a confidentiality agreement with it on September 29, 2026, to consider, evaluate and negotiate a transaction. Advent International, L.P. and Advent International GP, LLC each report beneficial ownership of 62,493,676 shares, or 58.54%. Advent International GPE IX Limited Partnership reports 16,955,510 shares (15.88%), and Advent International GPE IX-H Limited Partnership reports 5,428,915 shares (5.09%). The percentages use 106,744,713 shares outstanding as of August 6, 2026. The reporting persons state they had not effected transactions in Common Stock since the original statement.

The agreement includes 12-month non-solicitation and standstill provisions, subject to exceptions and, for certain actions, the issuer’s prior written consent. It generally limits disclosure and use of confidential information, with stated exceptions. Advent International, L.P. intends to continue engaging with the Special Committee and third parties, including Mr. Krantz, regarding a transaction.

Key Figures

Beneficial ownership reported by Advent International, L.P. and Advent International GP, LLC: 62,493,676 shares each Beneficial ownership reported by Advent International GPE IX Limited Partnership: 16,955,510 shares Beneficial ownership reported by Advent International GPE IX-H Limited Partnership: 5,428,915 shares +3 more

6 metrics

Beneficial ownership reported by Advent International, L.P. and Advent International GP, LLC 62,493,676 shares each 58.54% of the class for each reporting person

Beneficial ownership reported by Advent International GPE IX Limited Partnership 16,955,510 shares 15.88% of the class

Beneficial ownership reported by Advent International GPE IX-H Limited Partnership 5,428,915 shares 5.09% of the class

Class A Common Stock outstanding 106,744,713 shares As of August 6, 2026; basis for reported ownership percentages

Non-solicitation provision 12 months Applies to the issuer’s executive officers

Standstill provision 12 months Certain actions are subject to prior written consent and exceptions

Key Terms

beneficially owned, Shared Voting Power, non-solicitation provision, standstill provision

4 terms

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared Voting Power regulatory

"Shared Voting Power 62,493,676.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

non-solicitation provision regulatory

"a 12-month non-solicitation provision with respect to the Issuer's executive officers"

standstill provision regulatory

"a 12-month standstill provision pursuant to which Advent LP agreed"

A standstill provision is an agreement that temporarily limits or pauses certain actions, such as debt payments, legal claims, or negotiations, usually during a specific period. It acts like a pause button, giving parties time to address issues or find solutions without additional complications. For investors, it provides reassurance that disputes or disruptions are temporarily halted, helping to protect their interests during uncertain times.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DH shares do the reporting persons beneficially own?

Advent International, L.P. and Advent International GP, LLC each reported beneficial ownership of 62,493,676 shares (58.54%). Advent International GPE IX Limited Partnership reported 16,955,510 shares (15.88%), and Advent International GPE IX-H Limited Partnership reported 5,428,915 shares (5.09%).

What restrictions are in the DH confidentiality agreement?

The agreement includes a 12-month standstill provision covering certain acquisitions, group participation, board representation and voting-related activity, subject to exceptions and prior written consent for certain actions. It also includes a 12-month non-solicitation provision concerning the issuer’s executive officers. Confidential information is generally limited to evaluation and negotiation of a transaction, subject to stated exceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 08:30 PM Accepted by SEC EDGAR 10/01/2026 - 08:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Definitive Healthcare Corp.

(Name of Issuer)

Class A Common Stock, $0.001 par value

(Title of Class of Securities)

24477E103

(CUSIP Number)

Neil Crawford
Advent International, L.P., Prudential Tower, 800 Boylston Street
Boston, MA, 02199
617-951-9488

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/29/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 24477E103

1

Name of reporting person

Advent International, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 62,493,676.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 62,493,676.00

11

Aggregate amount beneficially owned by each reporting person

62,493,676.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

58.54 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The reported percentage is calculated based on 106,744,713 shares of Class A Common Stock ("Common Stock") outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on August 10, 2026.

SCHEDULE 13D

CUSIP Number(s): 24477E103

1

Name of reporting person

Advent International GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 62,493,676.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 62,493,676.00

11

Aggregate amount beneficially owned by each reporting person

62,493,676.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

58.54 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The reported percentage is calculated based on 106,744,713 shares of Common Stock outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the SEC on August 10, 2026.

SCHEDULE 13D

CUSIP Number(s): 24477E103

1

Name of reporting person

Advent International GPE IX Limited Partnership

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 16,955,510.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 16,955,510.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

16,955,510.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

15.88 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The reported percentage is calculated based on 106,744,713 shares of Common Stock outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the SEC on August 10, 2026.

SCHEDULE 13D

CUSIP Number(s): 24477E103

1

Name of reporting person

Advent International GPE IX-H Limited Partnership

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,428,915.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,428,915.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,428,915.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.09 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The reported percentage is calculated based on 106,744,713 shares of Common Stock outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the SEC on August 10, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, $0.001 par value
(b)	Name of Issuer: Definitive Healthcare Corp.
(c)	Address of Issuer's Principal Executive Offices: 492 Old Connecticut Path, Suite 401, Framingham, MASSACHUSETTS , 01701.
Item 1 Comment: The following constitutes Amendment No. 1 ("Amendment No. 1") to the Schedule 13D filed by the undersigned with the SEC on September 2, 2026 (the "Original Schedule 13D" and, as amended, the "Schedule 13D"). Except as set forth herein, the Schedule 13D remains in full force and effect. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented to insert the following at the end thereof: Confidentiality Agreement On September 29, 2026, Advent LP entered into a confidentiality agreement (the "NDA") with the Issuer. The NDA provides that Advent LP generally will not disclose confidential information to any other person, except to its representatives and Mr. Krantz, other third parties with respect to which the Issuer provides prior written approval and potential funding sources with respect to which the Issuer provides written approval, among others, and will not use confidential information except for the purpose of considering, evaluating and negotiating a transaction with the Issuer. The NDA also includes a 12-month non-solicitation provision with respect to the Issuer's executive officers and a 12-month standstill provision pursuant to which Advent LP agreed not to make certain acquisitions of securities or assets of the Issuer, join or participate in a "group" formed after the date of the NDA, seek additional representation on the Issuer's board of directors or advise or influence any person with respect to the voting of any securities of the Issuer, in each case without the prior written consent of the Issuer and subject to certain exceptions. In accordance with the NDA, Advent LP intends to continue to engage with the Special Committee and third parties, including Mr. Krantz, regarding a transaction with the Issuer. References to the NDA do not purport to be complete and are qualified in their entirety by reference to the confidentiality agreement, a copy of which is attached hereto as Exhibit 99.6, and incorporated herein by reference in its entirety.
Item 5.	Interest in Securities of the Issuer
(c)	The Reporting Persons have not effected any transactions in Common Stock since the filing of the Original Schedule 13D.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 of the Schedule 13D is hereby amended and supplemented to incorporate by reference at the end thereof, the information set forth in Item 4 of this Amendment No. 1.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.6 Confidentiality Agreement, dated September 29, 2026.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Advent International, L.P.

Signature:	/s/ Neil Crawford
Name/Title:	Neil Crawford / Senior Director, Fund Administration of Advent International GP, LLC, its General Partner
Date:	10/01/2026

Advent International GP, LLC

Signature:	/s/ Neil Crawford
Name/Title:	Neil Crawford / Senior Director, Fund Administration
Date:	10/01/2026

Advent International GPE IX Limited Partnership

Signature:	/s/ Neil Crawford
Name/Title:	Neil Crawford / Senior Director, Fund Administration of Advent International GP, LLC, its indirect General Partner
Date:	10/01/2026

Advent International GPE IX-H Limited Partnership

Signature:	/s/ Neil Crawford
Name/Title:	Neil Crawford / Senior Director, Fund Administration of Advent International GP, LLC, its indirect General Partner
Date:	10/01/2026

Comments accompanying signature:

Each of Advent International GPE IX Limited Partnership and Advent International GPE IX-H Limited Partnership, By: GPE IX GP Limited Partnership, their General Partner, By: Advent International GPE IX, LLC, its General Partner, By: Advent International, L.P., its Manager, By: Advent International GP, LLC, its General Partner.